Primary Record
137391-68-5
- In stock
- 1,921 g
- Purity
- 98.4 %
- CAS
- 137391-68-5
Compound Identifiers & Properties
- CAS
- 137391-68-5
- PubChem CID
- 57009450
- SMILES
- C[C@H]([C@@H]1[C@H](NC1=O)[C@@H](C)C(=O)C(=[N+]=[N-])C(=O)OCC2=CC=C(C=C2)[N+](=O)[O-])O
- Canonical SMILES
- C[C@@H](O)[C@H]1C(=O)N[C@@H]1[C@@H](C)C(=O)C(=[N+]=[N-])C(=O)OCc1ccc([N+](=O)[O-])cc1
Names & Synonyms
- 137391-68-5
- Meropenem Impurity 13
- Etapenem lmpurity 40
- Meropenem Impurity 16
- GEJ8U54SJZ
- Meropenem intermediates F9
- Meropenemintermediates(F9)
- SCHEMBL306132
- C17H18N4O7
- (R)-4-Nitrobenzyl 2-diazo-4-((2R,3S)-3-((R)-1-hydroxyethyl)-4-oxoazetidin-2-yl)-3-oxopentanoate
- CTK8C0549
- DTXSID10720045
- FDXUXRZSNNSUGD-NRMKKVEVSA-N
- 90822-24-5
- ANW-64881
- MFCD11111990
- ZINC35635583
- AKOS016005347
- FH38865
- CID11234678
- AJ-91921
- CID 11234678
- FM172290
- F-9 (M-6)
- TC-153626
- ST24035497
- J1.315.675A
- F71147
- (4-NITROPHENYL)METHYL (4R)-2-DIAZO-4-[(2R,3S)-3-[(1R)-1-HYDROXYETHYL]-4-OXOAZETIDIN-2-YL]-3-OXOPENTANOATE
- 2-Azetidinebutanoic-alpha-14C acid, alpha-diazo-3-(1-hydroxyethyl)-gamma-methyl-beta,4-dioxo-, (4-nitrophenyl)methyl ester, [2R-[2alpha(R*),3beta(R*)]]- (9CI)
- Meropenem intermediate F9(Discontinued,See C4X-130916)
- (3S,4R)-3-[(1R)-1-Hydroxyethyl]-4-[(1R)-1-methyl-3-diazo-3-(p-nitrobenzyloxycarbonyl)-2-oxopropyl]az
- (3S,4R)-3-[(1R)-1-Hydroxyethyl]-4-[(1R)-1-methyl-3-diazo-3-(p-nitrobenzyloxycarbonyl)-2-oxopropyl]azetidin-2-one
- 4-Nitrobenzyl (R)-2-Diazo-4-[(2R,3S)-3-[(R)-1-hydroxyethyl]-4-oxo-2-azetidinyl]-3-oxopentanoate
- (R)-4-Nitrobenzyl 2-diazo-4-((2R,3S)-3-((R)-1-hydroxy-ethyl)-4-oxoazetidin-2-yl)-3-oxopentanoate
- 4-Nitrobenzyl (R)-2-diazo-4-((2R,3S)-3-((R)-1-hydroxyethyl)-4-oxoazetidin-2-yl)-3-oxopentanoate
- (3S,4R)-3-[(1R)-1-Hydroxyethyl]-4-[(1R)-1-methyl-3-diazo-3- (p-nitrobenzyloxycarbonyl)-2-oxopropyl]azetidin-2 -one
- (3S,4R)-3-[(1R)-1-Hydroxyethyl]-4-[(1R)-1-methyl-3-diazo-3-(4-nitrobenzyloxycarbonyl)-2-oxopropyl]azetidin-2-one
- (4-Nitrophenyl)methyl (?R,2R,3S)-?-diazo-3-[(1R)-1-hydroxyethyl]-?-methyl-?,4-dioxo-2-azetidinebutanoate
- (4-nitrophenyl)methyl (4R)-2-diazo-4-[(2R,3S)-3-[(1R)-1-hydroxyethyl]-4-oxo-azetidin-2-yl]-3-oxo-pentanoate
- (4-Nitrophenyl)methyl (gammaR,2R,3S)-alpha-diazo-3-[(1R)-1-hydroxyethyl]-gamma-methyl-beta,4-dioxo-2-azetidinebutanoate
- (4R)-2-Diazo-3-oxo-4-[(2R,3S)-4-oxo-3-[(1R)-1-hydroxyethyl]azetidine-2-yl]valeric acid 4-nitrobenzyl ester
- (4R)-2-diazonio-4-[(2R,3S)-3-[(1R)-1-hydroxyethyl]-4-oxoazetidin-2-yl]-1-[(4-nitrophenyl)methoxy]-1-oxopent-2-en-3-olate
- (4R)-2-Diazonio-4-{(2R,3S)-3-[(1R)-1-hydroxyethyl]-4-oxoazetidin-2-yl}-1-[(4-nitrophenyl)methoxy]-1-oxopent-2-en-3-olate
- (GAMMAR,2R,3S)-ALPHA-DIAZO-3-[(1R)-1-HYDROXYETHYL]-GAMMA-METHYL-BETA-4-DIOXO-2-AZETIDINEBUTANOIC ACID (4-NITROPHENYL)METHYL ESTER
- (R)-4-[(2R,3S)-3-[(R)-1-Hydroxyethyl]-4-oxoazetidine-2-yl]-2-diazo-3-oxovaleric acid 4-nitrobenzyl ester
- 2-Azetidinebutanoic acid, alpha-diazo-3-(1-hydroxyethyl)-gamma-methyl-beta,4-dioxo-, (4-nitrophenyl)methyl ester, [2R-[2alpha(R*),3beta(R*)]]-
- 2-Azetidinebutanoic acid, alpha-diazo-3-[(1R)-1-hydroxyethyl]-gamma-methyl-beta,4-dioxo-, (4-nitrophenyl)methyl ester, (gammaR,2R,3S)-
- 2-Azetidinebutanoic-|A-14C acid, |A-diazo-3-(1-hydroxyethyl)-|A-methyl-|A,4-dioxo-, (4-nitrophenyl)methyl ester, [2R-[2|A(R*),3|A(R*)]]- (9CI)
- 2-Azetidinebutanoic-a-14c acid,a-diazo-3-(1-hydroxyethyl)-g-methyl-b,4-dioxo-,(4-nitrophenyl)methyl ester,[2r-[2a(r*),3b(r*)]]-(9ci)
- 4-nitrobenzyl (4R)-2-diazo-4-[(2R, 3S)-3-{(1R)-1-hydroxyethyl}-4-oxoazetidin-2-yl]-3-oxopentanoate
- 4-nitrobenzyl (4R)-2-diazo-4-[(2R,3S)-3-{(1R)-1-hydroxyethyl}-4-oxoazetidin-2-yl]-3-oxopentanoate
- 4-nitrobenzyl (4R)-2-diazo-4-[(2R,3S)-3-{(1R)-1-hydroxyethyl}-4-oxoazetidin-2-yl]3-oxopentanoate
- 4-nitrobenzyl (4R)-2diazo-4[(2R,3S)-3-{(1R)-1-hydroxyethyl}-4-oxoazetidin-2-yl]3-oxopentanoate
- 4-Nitrobenzyl(R)-2-diazo-4-((2R,3S)-3-((R)-1-hydroxyethyl)-4-oxoazetidin-2-yl)-3-oxopentanoate-2-14C
- 86421-06-9
- F9